

Astellas Announces Management Structure

TOKYO, February 5, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the following Executive Committee Standing Members effective from April 1, 2020.

1. Executive Committee*¹ Standing Members (as of April 2020)

Title	Name	New
Representative Director, President and Chief Executive Officer (CEO)	Kenji Yasukawa	
Representative Director, Corporate Executive Vice President, Chief Strategy Officer (CStO) and Chief Financial Officer (CFO)	Naoki Okamura	
Chief Administrative Officer (CAO) and Chief Ethics & Compliance Officer (CECO)	Fumiaki Sakurai	
Chief Medical Officer (CMO)	Bernhardt Zeiher	
Chief Commercial Officer (CCO)	Yukio Matsui	
General Counsel* ²	Catherine Levitt	✓

***1 Executive Committee:** an organization that discusses important matters of management across Astellas. It is chaired by the Representative Director, President and CEO, and comprises Top Management and the General Counsel as standing members. Extended members include the heads of research, development, pharmaceutical technology, and commercial divisions, who will participate in any necessary discussions at the request of the chairman.

***2 General Counsel:** head of Legal

2. Resignation effective on March 31, 2020

Name	Current Title
Linda Friedman	General Counsel

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <https://www.astellas.com/en>

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473